PEG-MGF

Research-Grade

PEG-MGF (PEGylated Mechano Growth Factor) is a modified form of the IGF-1Ec splice variant, commonly known as Mechano Growth Factor (MGF). MGF is produced naturally in response to mechanical loading of muscle tissue — it is the form of IGF-1 that skeletal muscle expresses after exercise or damage, and it plays a critical role in activating satellite cells (muscle stem cells) to begin the repair and hypertrophy process. The native MGF peptide has an extremely short plasma half-life (minutes), making systemic administration impractical. PEGylation — the attachment of a polyethylene glycol chain — extends the circulating half-life from minutes to hours, allowing systemic injection rather than requiring direct intramuscular delivery to the target tissue. MGF's mechanism is distinct from mature IGF-1: while IGF-1 promotes myoblast differentiation (committing satellite cells to become muscle fibers), MGF promotes satellite cell proliferation (expanding the pool of repair cells before they differentiate). This proliferative phase is essential — without sufficient satellite cell activation, muscle repair capacity is limited. Preclinical studies have demonstrated that MGF administration increases satellite cell numbers, accelerates muscle repair after injury, and may contribute to cardiac repair following ischemia. However, the human evidence base is essentially nonexistent. No controlled clinical trial of PEG-MGF has been published. The research peptide market sells PEG-MGF widely, but the compound presents significant challenges: PEGylation quality varies between suppliers, the optimal PEG chain length for biological activity is not standardized, and the balance between extended half-life and receptor binding affinity is poorly characterized in humans.